Nice mention in the SUnday Telegraph today.

NeutraHealth

The dietary supplements sector is growing in popularity as consumers become more health conscious; half the population is estim-ated to take vitamin supplements.

Neutra-Health (11.5p) listed on Aim in February last year as a shell company with the intention of acquiring manufacturers in the dietary supplements industry. The company has already made two acquisitions since its February 2005 flotation and is believed to be talking to potential targets about another deal in the coming months.

Acquisitions to date are BioCare, a -Birmingham-based manufacturer and distributor of natural health products, and Nutrigold, a company that makes products such as the "detox in a box" health treatment.

Neutra-Health's sales are expected to grow from 2.4m last calendar year to 9.3m this year, and profit is expected to grow from 400,000 to 1.6m. The nutraceuticals sector is growing by 10 to 15 per cent a year. Impetus will be added by an aging population - which is more likely to take supplements - and EU laws that make it harder for small companies to compete, meaning that consolidation is inevitable. The company will launch branded travel products into the retail market later this year and has just launched a transactional website for BioCare.

It also has a strong board - non-executive directors include Sir Gulam Noon, the curry entrepreneur, and Martin Gatto, a former finance director of Somerfield, the supermarket group. Buy.

Bear in mind the market capitalisation is a mere 16.65million and estimated turnover 9million - looks good.

Its been a while in coming, but this health supplement supplier looks to have some good businesses together and the share price has made a break out to the upside this morning.

Patrick Holford, leading nutrition commentator/author has teamed up with Biocare(NUT). In footballing terms it's like signing the Thierry Henry of the vitamin world!!!

He is developing an extensive range of vitamin supplements which should propel this little company up the league of nutritional supplement suppliers.
Check out www.biocare.co.uk

Directors have bought shares in past fortnight.

All looks good for growth.

Director bought 1,000,000 shares, about 120,000 investment last week.

http://www.neutrahealthplc.com/

16 October 2007


NEUTRAHEALTH PLC ('the Company')

CHANGES TO BRUNEL EARN OUT & ISSUE OF SHARE OPTIONS


NeutraHealth is pleased to announce changes to the earn out agreement for the
vendors of Brunel Healthcare Limited ('Brunel'), and the issue of share options
to Mr Ron Stagg, Managing Director and co-founder of Brunel and a Director of
NeutraHealth.

Brunel Healthcare Earn Out

NeutraHealth acquired Brunel in January 2007 for initial consideration of 4
million. Brunel distributes private label and branded vitamins & supplements,
and over the counter ('OTC') medicines to major national retailers. Branded
products, including the Vertese range of gelatin free supplements, are
distributed through Alliance Boots, Tesco, Holland & Barrett, Superdrug,
Waitrose and others.

At the time of acquisition, an agreement with the vendors was put in place for
an additional 1.9 million of further cash consideration to be paid on attaining
growth in PBIT through to December 2008. The performance of Brunel to date has
exceeded initial expectations and the Brunel team, especially Mr Ron Stagg, has
made a significant contribution to the overall Group. As a result, the earn out
agreement has been amended as follows:

If 2008 performance conditions are met by 31 December 2007, which is
expected, a total earn out consideration of 1.5 million will become
guaranteed; and

The maximum total earn out consideration available will be reduced
from 1.9 million to 1.5 million.

If the performance conditions are attained, the original timing of payments will
be unchanged with 0.8 million and 0.7 million being paid in March 2008 and
March 2009 respectively.

Making the change reduces the maximum future earn out liability of NeutraHealth
by 0.4 million, and helps NeutraHealth progress strategic initiatives more
quickly, benefiting from the Brunel team's greater involvement across the whole
Group.

Share options

As Mr Stagg is now playing a greater role in the overall development of the
Group, rather than just taking responsibility for Brunel, he has been granted
performance related options over 2,500,000 Ordinary Shares of 10p each in the
Company ('Ordinary Shares').

All of the options granted were issued at the market price at market close on 12
October 2007 of 12.5p. The options are exercisable in whole or in part two years
after being granted and are subject to a minimum market value of 20p for the 10
consecutive business days prior to the date of any exercise. The options will
lapse if not exercised within ten years of the date of grant. The grant was made
on 15 October 2007.

Following the grant of options, Mr Stagg now has options over 2,500,000 Ordinary
Shares, and is interested in 1,000,000 Ordinary Shares, representing 0.6 per
cent. of the Ordinary Share capital of the Company, all of which are held
beneficially

Following the grant of options, the aggregate number of Ordinary Shares under
option pursuant to any Company option scheme is within the limit described
further in the admission document relating to the re-admission of NeutraHealth
to AIM on 31 August 2005 following completion of the acquisition of BioCare
Limited. The total number of options over Ordinary Shares which have been
granted pursuant to the Company's option schemes is 27,369,582 and the number of
new shares issuable pursuant to such options represents 15.6% of the Company's
issued Ordinary Share capital. These include options over 4,213,500 Ordinary
shares representing 2.4% of the Company's issued Ordinary Share capital which
are exempt from the limits described in the admission document referred to
above.

Michael Toxvaerd, NeutraHealth Chief Executive, commented:

'The performance of Brunel has exceeded expectations since its acquisition by
NeutraHealth, and this is a very positive step forward. Mr Stagg is increasingly
contributing to the Group's strategic development, and the grant of share
options aligns his interests with those of shareholders as NeutraHealth focuses
on delivering continued growth in sustainable earnings.'


For more information:

Further information for investors is available on the Company's website at

www.neutrahealthplc.com/



NeutraHealth plc
Martin Gatto, Chairman 07778 749 223
Michael Toxvaerd, Chief Executive 07730 581 584
Robin Hilton, Finance Director 07738 018 411

KBC Peel Hunt (Nominated Adviser and Broker)
Matt Goode 020 7418 8900

Pelham Public Relations
James Henderson 020 7743 6672
Gavin Davis 020 7743 6677


Notes:

NeutraHealth was floated on AIM in February 2005 with the strategy of
consolidating the fragmented Vitamins, Minerals and Supplements sector of the
growing nutraceutical market. The company is focused on building a group of
companies within the nutraceutical market which will deliver growth through
organic expansion and through strategic acquisitions.

The company made its first acquisition, BioCare, in August 2005 for 16.1m.
Since then it has delivered the following:

February 2006

Second acquisition (0.5m) of Nutrigold, a producer of nutraceutical
products and services for the practitioner market. The founder, Andy Wren,
has remained as managing director with an earn out incentive up to 0.3m

December 2006

Agreement reached with Boots the Chemist plc, Waitrose, Harrods,
Selfridges, Holland & Barrett, and The Nutri Centre (51% owned by Tesco) to
stock the TravelGuard range, NeutraHealth's first retail brand.

January 2007

Signing of an exclusive licensing agreement with the Champneys Spa Group to
develop a new health and beauty range of vitamins and supplements sold
through major retail outlets under the Champneys name.

January 2007

Third acquisition (4.0m) Brunel Healthcare Limited, an established
supplier of nutraceutical products and over the counter medicines sold by
major retailers across the UK.

April 2007

Signed three year agreement with the UK's leading high street retailer of
vitamins, minerals and supplements to continue to supply products under
private label until at least August 2010, contractually underpinning 20%
of current group sales

July 2007

Fourth acquisition (0.4m) Health Products for Life, a direct to consumer
website

Signing of licensing agreement with leading nutrition expert Patrick
Holford

August 2007

Net 5.3 million investment in 20% of NeutraHealth by Elder Pharmaceuticals
Limited of India through issue of shares at 16p

Investment made at a 36% premium to mid-market price on day of announcement

Funds raised for future acquisitions, and opportunities for distribution
and manufacturing between businesses

Some nice upward price action. Still undervalued though. Biocare is a fantastic business.
Pe ratio extremely modest at present given growth potential.

How does this Look Good? - the sp has halved over the last year . . . in line with Markets generally I might agree, but I thought their sales were increasing....so that would even things out?

Do you have a handle on the Debt position? I understand they bought the Bristol business for Cash and shares......what's the story about Debt?
((These markets hate debt, because the Interest% is not certain and concern Banks could call-in.))

EDIT:17June08...Ah so they are selling one half and buying another - to focus on one aspect alone. This is a good plan for a small business - know your customers, etc. yet the mention supermarkets as existing customers (of the purchase) - yet we know they have great power and squeeze suppliers. . .. . . these are dark days and raising money is still an issue......unless you know different.